Rituxan
FDA Approves Rituxan Plus Chemotherapy for Pediatric Hematologic Cancers
The FDA approved rituximab (Rituxan, Genentech) in combination with chemotherapy for pediatric patients (≥6 ...
DECEMBER 8, 2021
FDA Approves Riabni, Third Biosimilar to Rituxan
The FDA Approved Amgen's Riabni, the 3rd biosimilar to the originator, U.S.-licensed Rituxan.
DECEMBER 18, 2020
FDA Approves Pfizer Biosimilar to Rituxan
The FDA approved rituximab-pvvr (Ruxience, Pfizer), a biosimilar to rituximab (Rituxan, Genentech), for several ...
JULY 25, 2019
FDA Approves Truxima, First Biosimilar to Rituxan
The FDA approved rituximab-abbs (Truxima, Celltrion/Teva), the first biosimilar to rituximab (Rituxan, ...
DECEMBER 1, 2018
Rituxan Hycela Approved for FL, DLBCL, CLL
Rituximab and hyaluronidase human (Rituxan Hycela, Genentech) was approved for subcutaneous injection for the ...
JUNE 23, 2017
SABRINA Trial Indicates Subcutaneous Rituximab Equivalent to IV Form
A formulation of rituximab administered by subcutaneous injection appears to be just as safe and effective in the ...
JUNE 1, 2017
Post-Lymphoma Primary Malignancies Changed by Rituximab
New research provides a snapshot of how the advent of rituximab (Rituxan, Genentech) has changed the occurrence of ...
AUGUST 9, 2016